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Abstract 
Aim: The link between chemotherapy treatment and cardiotoxicity is well established, 
particularly for adults with blood cancers. However, it is less clear for children. This analysis 
aimed to compare the trajectory and mortality of children and adults who received 
chemotherapy for blood cancers and were subsequently hospitalised for heart failure. 
Methods: Linked data from the Queensland Cancer Registry, Death Registry and Hospital 
Administration records for initial chemotherapy and later heart failure were reviewed (1996-
2009). Of all identified blood cancer patients (N=23,434); 8,339 received chemotherapy, 
including 817 children (aged ≤18 years at time of cancer diagnosis) and 7,522 adults. Time-
varying Cox proportional hazards regression models were used to compare the characteristics 
and survival between the two groups.  
Results: Of those who were subsequently hospitalised for heart failure, 70% of children and 
46% of adults had the index admission within 12 months of their cancer diagnosis. Of these, 
53% of the pediatric heart failure population and 71% of the adult heart failure population 
died within the study period. Following adjustment for age, sex and chemotherapy 
admissions, children with heart failure had an increased mortality risk compared to their non-
heart failure counterparts, a difference which was much greater than that between the adult 
groups.  
Conclusion: The impact of heart failure on children previously treated for blood cancer is 
more severe than for adults, with earlier morbidity and greater mortality. Improved strategies 
are needed for the prevention and management of cardiotoxicity in this population.  
Keywords: cardiology, cardiotoxicity, chemotherapy, heart failure, adult, pediatric 
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Introduction 
Cardiotoxicity is a well-established adverse consequence of cancer treatment, with 
drugs used to treat blood cancers known to have long-term cardiovascular effects 
including left ventricular dysfunction, myocardial ischemia, hypertension and QTc 
prolongation.1, 2 These cardiotoxic agents are widely used in both children3 and adults.4  
In the general population, the median age of heart failure (HF) diagnosis typically 
ranges from 70 to 83 years and is extremely uncommon in children.5-8 However, 
children previously treated for cancer are 5.9 times more likely to develop congestive 
heart failure than their nearest age sibling.9 Furthermore, in the absence of overt HF in 
childhood, even small changes in ejection fraction from chemotherapy in childhood 
predispose adult survivors of childhood cancer to HF as they age.10  
Studies indicate that the pathogenesis underlying chemotherapy-related cardiovascular 
changes operates on a cellular level.11-13 While this affects people of all ages, it is likely 
that the impact of chemotherapy treatment on a heart which is still developing will be 
different to that on a mature organ. Research has shown that cardiotoxicity can manifest 
up to 20 years after cancer therapy, and with improving survival rates, particularly from 
childhood cancer,14, 15 this impact is likely to become even more pronounced.16-18 This 
confers a need to further understand the characteristics of heart failure development in 
children previously treated for cancer.   
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Previous work from our research group has demonstrated that in a cohort of patients 
with breast or blood cancer (n=15,987), 6.6% of patients treated with chemotherapy 
were later hospitalised for heart failure.19 The median age of this population was 55.0 
years (IQR, 44–65), and included 817 (5.1%) patients aged 18 years or under. The 
purpose of this secondary analysis is to compare the characteristics and survival 
outcomes of children and adults in order to identify differences in the incidence, time to 
diagnosis and associated mortality rates.   
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Methods  
Study design 
The parent study was a retrospective audit of linked health administration data from 
Queensland, Australia. Approval was granted by the Metro South Health Service 
District Human Research Ethics Committee (HREC/11/QPAH/600). 
Data sources and data linkage 
Three independent databases were linked to create the analysis database for this study: 
(1) the Queensland Cancer Registry (QCR), (2) the Queensland Hospital Admitted 
Patient Data Collection, and (3) the Queensland Birth, Deaths and Marriages Registry.  
The QCR houses data from all persons admitted to public and private hospitals and 
nursing homes with a cancer diagnosis in Queensland since 1982.20 The initial 
population of interest was identified from this by selecting patients registered between 
January 1996 and December 2009 with a primary diagnosis of blood cancer. These 
dates were chosen to ensure a uniform time frame across all data sets. 
The Hospital Admitted Patient Data Collection contains data on all hospital separations 
from any Queensland hospital permitted to admit patients. The QCR facility and Unit 
Record (UR) numbers were match-merged with admissions episodes from the same 
time period to identify those who received chemotherapy treatment. These records 
formed the study cohort. 
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The hospital admissions were further interrogated to stratify the members of the cohort 
with an index HF separation versus those without. The index HF episode must have 
occurred after the date of cancer registry entry to be included in the HF group.  
Finally, the study cohort records were linked to the Queensland Birth, Deaths and 
Marriages database - a repository for all registered deaths in Queensland. All-cause 
mortality data were then extracted to complete the database. LinkageWiz software was 
used for probabilistic matching.21 
Participants 
The primary cancer diagnosis recorded in the QCR was used to identify blood cancers 
using the International Classification of Diseases and Tenth Revision Australian 
Modification (ICD 10-AM) and ICD-O (oncology) site codes ICD10-AM: C42, C77 
and ICD-O: M9590/3-M9989/3.  
Patients prescribed chemotherapy were identified from the relevant codes in the hospital 
records, defined according to ICD-9-CM (clinical modification) (99.25) and ICD-10-
AM (Australian Modification) (96196-00, 96199-00, 96209-00, 96207-00, 96208-00, 
96204-00, 13942-00, 13915-00, 13918-00, 13921-00, 13927-00, 13939-00, 13942-00, 
Z51.1, Z51.2). 
Blood cancer patients who were identified as having received chemotherapy treatment 
were stratified by age group (children: aged 18 years and under; adult: over 18 years). 
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Participants were then categorised into those who had an index HF admission after 
cancer diagnosis (HF group) compared with those who did not (non-HF group). An 
index HF admission was defined as a patient’s first hospitalisation coded for HF. HF 
diagnosis was based on the ICD-9-CM (428.0. 428.1 and 428.9) and ICD-10-AM 
(I50.0, I50.1 and I50.9) codes and included Congestive HF, Left Ventricular failure and 
other unspecified cardiomyopathies.  
Outcome, exposure and confounders 
The primary outcomes were (1) mortality and (2) HF which occurred after blood cancer 
diagnosis and treatment; indicated by an index hospital admission coded for HF. Both 
incidence and the time to index HF admission and/or death were measured. 
Possible confounders include demographic characteristics and clinical features such as 
income, education, medical history, chemotherapy agent and dose, and other treatment 
modalities such as transplantation or concurrent radiotherapy treatment. 
Statistical analysis 
Data management and statistical analyses were performed using STATA version 14.0 
(StataCorp LP, College Station, TX, USA). Means and standard deviations (SD) for 
discrete and continuous data were calculated and categorical variables were presented as 
percentages.  
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Differences in demographics and cancer treatment history were analysed for between-
group differences using Fisher’s exact and chi-square tests. Where continuous data were 
non-normally distributed, the data are presented as median (inter-quartile range) (IQR) 
and compared using appropriate non-parametric tests. Differences were considered 
significant at p<0.05. 
The time-varying Cox proportional hazards regression models were used to evaluate 
factors associated with mortality risk during follow-up within groups adjusted by 
demographic variables and cancer treatment history (Table 2). Hazard ratios (HR) were 
used to describe the probability of survival after chemotherapy treatment in each group. 
The proportional hazard assumptions as well as goodness of fit of the models were also 
tested.  
Kaplan-Meier survival curves were derived to compare the time to death from QCR 
registration between HF and non-HF groups for both adults and children, adjusted for 
sex and age using a log-rank test.  
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Results 
Participants 
The inclusion of participants is described in accordance with the STrengthening the 
Reporting of OBservational studies in Epidemiology (STROBE) flow chart22 (Figure 
S1). 
A total of 30,612 hematologic cancer records in the QCR were linked to hospital 
admissions and death records. Within the QCR, there were 625 patients registered with 
multiple cancers - the primary cancer diagnosis was used and all other registrations 
were excluded. 
6,553 records were excluded as they fell outside the study timeframe, and a further 
15,095 records were excluded as these patients did not receive chemotherapy. The final 
sample consisted of N=8,339 patients; N=817 children, and N= 7,522 adults. Of these, 
N=30 (3.7%) children and N=852 (11.3%) adults had an index HF admission recorded 
after their cancer diagnosis.  
Of those in the child HF group, N=16 (53.3%) patients died within the 13 year study 
period, while in the non-HF group N=114 (14.5%) patients died within the study period. 
In the adult HF group, N=601 (70.5%) patients died within the study period compared 
to N=2,414 (36.2%) patients in the adult non-HF group.   
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Demographics and clinical characteristics 
Demographic information was extracted from the QCR (Table 1). Within the adult 
study population, there were significant differences in the median age at cancer 
diagnosis, the median number of chemotherapy admissions and the quintiles of 
chemotherapy admissions between those who developed HF and those who did not. 
However these differences were not observed in the child population (Table 1). 
Outcome data 
Of those who had an index HF admission after chemotherapy (children N=30 and adults 
N=852), 70.0% of the children compared to 46.4% of adult patients were admitted for 
HF within 12 months of their initial cancer diagnosis (Figure 1). Furthermore, a total of 
83.3% of the children compared to 69.3% of adult patients were admitted for HF within 
the first 3 years of cancer diagnosis.  
All-cause mortality (adjusted for age, sex, and chemotherapy admissions) differed 
between groups, with both the child HF group (HR 4.86 (95% CI, 2.85–8.27), P<0.001) 
(Figure 2) and the adult HF group (HR 1.66 (95% CI, 1.51-1.82), P<0.001) (Figure 3) 
having a greater risk of mortality relative to the respective non-HF groups. Overall, the 
mortality rate was almost 4 times higher for children than for adults. 
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The adjusted time-varying Cox Proportional Hazard modelling showed that both child 
and adult non-HF patients along with adult HF patients had an increased risk of 
mortality with increasing age (Table 2). This was not significant in the child HF 
patients, but this likely reflects the low numbers in this group and the HR (1.02) was 
higher than the HR (1.01) for the adult HF group. Although there were no differences in 
mortality risk by sex or number of chemotherapy admissions between the HF and non-
HF child groups, there was a gender difference evident in the adult groups, with males 
having a higher risk of mortality for both the HF and non-HF groups than females 
(Table 2). 
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Discussion 
This secondary analysis aimed to compare the characteristics and clinical outcomes of both 
children aged ≤18 years and adults who received chemotherapy treatment for blood cancer, 
and were later admitted for HF, relative to those who were not admitted for HF. The ongoing 
risk of HF and its associated mortality following chemotherapy have been previously 
described2,4,13,3, although many prior studies were based on smaller datasets or did not 
incorporate comprehensive longitudinal follow up. We utilised data linkage to report the 
adjusted, long-term survival of an unselected cohort of patients who received chemotherapy 
for blood cancer in a state-wide database stratified according to whether or not they were 
later diagnosed with HF.  
The results of this study demonstrated that 3.7% of children and 11.3% of adults with 
chemotherapy-treated blood cancer had a later index admission for HF. These results are 
broadly consistent with other studies which have reported rates of cardiotoxicity following 
anthracycline treatment ranging from 0.9% - 26%23. Our results are likely to be 
underestimates, as we are reliant on hospital admission as an indicator for HF diagnosis and 
therefore cannot account for either sub-clinical presentation or HF treated in primary care 
only. The maximum 13 year follow up time of this study is insufficient to fully capture the 
late onset incidence of HF or HF-related death; especially in those who were treated for 
cancer as children; which is believed to occur up to 20 years after initial cancer treatment.3 
While the adult population showed significant differences in both median age and number of 
chemotherapy separations between HF and non-HF groups, this analysis did not reach 
significance within the children.  This is likely due to both the smaller sample size and the 
narrower age range of the children.   
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Although the proportion of the children who were admitted for HF during the study period 
was lower than the adult sample (3.7% v 11.3% respectively, Table 1), a high proportion of 
these recorded an index admission in the first 12 months after cancer diagnosis (Figure 1). Of 
the 30 HF children, 70.0% (n=21) had an index admission within the first 12 months of their 
cancer diagnosis compared to 46.4% (n=395) of the adults.   For those children who were 
admitted for HF, there was an almost 4 times greater mortality risk than for children with 
cancer alone, significantly more than the difference between the adult groups where the risk 
was almost double in the HF group compared to the non-HF group. This may reflect the 
decreased likelihood that children have additional comorbidities or competing causes of 
death, such that the relative effect of developing HF will be more pronounced. Alternatively, 
it may be that their hearts are more sensitive to the effects of chemotherapy, or they are less 
likely to tolerate or respond to HF management. 
While the current cardiac screening recommendations for individuals previously diagnosed 
with cancer and treated with known cardiotoxins include increased frequency of screening 
based on younger age at treatment and higher dosage of chemotherapy;11, 24 even these 
precautions do not appear to be sufficient to mediate the differences in outcomes between 
children and adults who subsequently develop HF. 
Clinical Implications  
An observation from this study is the potentially high rate of early onset of HF detected in the 
pediatric HF population. While the absolute numbers are small (21 out of 30 children who 
had a HF admission had the index admission in the first 12 months after cancer diagnosis), 
the absolute incident rate of child HF admissions is half that seen in the adult HF population. 
However comparison with an age-matched general population cohort, (calculated using 
unpublished admissions data from SA Health, 2010-2012), reveals that while the adult HF 
admission incidence in the first 12 months after cancer treatment is  over 200 times the 
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population rate of HF admissions (adult HF 5,251 per 100,000 vs population 25.3 per 
100,000), the pediatric HF admission incidence is over 600 times the population rate 
(pediatric HF 2,570 per 100,000 vs population 4.1 per 100,000). While the higher proportion 
of early onset cases in the children may reflect delayed diagnosis in the adult cohort, these 
incident rates suggest that there may be a significant pattern of early onset HF after cancer 
diagnosis in children vs adults. This pattern is not explicitly reported in the trials of 
management of hematologic malignancies where the focus is often on the long-term cardiac 
risk to patients.25-27 Furthermore, children are often excluded from clinical trials due to 
ethical concerns.
Current guidelines for the treatment of cancer in children recommend that cumulative 
anthracycline dose be limited to ≤250-300mg/m2, with similar guidelines also given for other 
chemotherapy and radiation treatments.2, 28  Survivorship guidelines also recommend cardiac 
monitoring for a number of years for both children and adults who have received cardiotoxic 
chemotherapy and radiotherapy. In children, recommended cardiac imaging frequency is 
anywhere from 1 to 5 yearly, depending on the age of the child at treatment, the cumulative 
chemotherapy dose, and whether radiotherapy treatment was also undertaken.28 
While the balance between providing therapeutic levels of treatment and the risk of 
cardiotoxicity is difficult to navigate, this analysis reinforces the need for clinicians to 
consider both short term and long-term risk when deciding on chemotherapy dosage. While 
adverse effects might be unavoidable in some situations, the need for early and intensive 
monitoring – including during treatment – especially in children, is clearly necessary to 
reduce the severity and impact of subsequent cardiac events. Additional evidence around the 
optimal mode and frequency of cardiac monitoring is required to clarify best practice for each 
age group. Meanwhile rigorous research into the use of cardioprotectants, appropriate 
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treatments for those with cardiac compromise, and the alternatives to cardiotoxic therapy, is 
also needed to build the evidence base for these therapies. 
Strengths and Limitations 
The strength of this study is the large sample size and the linkage process which enabled the 
identification of outcomes not usually recorded in isolated clinical data sets. While the results 
should be generalizable to any population of people who have been treated for blood cancers, 
there are some limitations to be considered beyond those already discussed above. 
We were not able to ascertain precisely which chemotherapy treatments patients received or 
who also received radiotherapy. It is well known that different chemotherapy agents can have 
different cardiac effects, 13, 23 and that concurrent chest irradiation can also contribute to the 
development of cardiotoxicity,29, 30 but these data were not available for linkage and could not 
be included in this analysis. Likewise we were not able to detect or control for any pre-
existing conditions which may predispose individuals to the development of heart failure. 
In the pediatric population, there was a short median follow-up time which was significantly 
different between the HF group and the non-HF group, with the non-HF group being 
followed for almost twice as long. However, this was largely explained by the shorter 
survival of the HF group with 50% dying within the study period compared to 14.5% of the 
non-HF group. Due to the short follow-up time for many patients, and existing evidence to 
suggest that adverse consequences of chemotherapy can present many years after treatment, 
the results of this study are likely to be an underestimate of the proportion of children who 
developed HF. 
Conclusion 
We identified different patterns of HF risk and trajectory between child and adult patients 
with blood cancer who received chemotherapy in this linked data set. The results of this study 
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reinforce the need for regular cardiovascular screening of all patients, especially in the first 
three years following cancer diagnosis and treatment. Given the potential for the rapid onset 
of HF in children, even more frequent screening and the implementation of early detection 
protocols during treatment and throughout the first year may be necessary to allow for prompt 
action to reduce the impact of HF, especially given the relatively poor outcomes for 
childhood cancer patients who develop HF. Future studies will also need to evaluate the 
uptake and tolerability of HF treatments, which have been largely informed from studies 
conducted in adult HF cohorts without cancer. 
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Table 1 Demographics and chemotherapy separation rates for adults (>18 years) and children (≤18 years) who received chemotherapy for blood 
cancer 
 
 Adults  N=7,522 (90.2%) Children  N=817 (9.8%) 
Characteristics 
Heart Failure 
N=852 (11.3%) 
Non-HF 
N=6,670 (88.7%) 
 
P-value 
 
Heart Failure 
N=30 (3.7%) 
Non-HF 
N=787 (96.3%) 
 
P-value 
 
Age (at cancer diagnosis), years 
Median (IQR) 
68 (60-75) 60 (48-69) P <0.001 5 (3-12) 7 (3-14) P=0.51 
Sex, N(%) 
Female 
Male 
 
357 (41.9) 
495 (58.1) 
 
2,752 (41.3) 
3,918 (58.7) 
P=0.72  
12 (40.0) 
18 (60.0) 
 
351 (44.6) 
436 (55.4) 
P=0.62 
 
Marital Status, n(%) 
Married/De Facto 
Single/divorced/widowed 
 
532 (62.4) 
320 (37.6) 
 
4,459 (66.8) 
2,211 (33.2) 
P=0.01  
- 
30 (100.0) 
 
13 (1.2) 
774 (98.4) 
- 
 
Country of Birth, n(%) 
Australia 
All Other Countries 
 
602 (70.7) 
250 (29.3) 
 
4,992 (74.9) 
1,678 (25.2) 
P<0.01  
30 (100.0) 
- 
 
723 (91.9) 
64 (8.1) 
 
- 
 
Residence (Postcode), N(%) 
Metropolitan 
Rural/Remote 
 
734 (86.2) 
118 (13.9) 
 
5,789 (86.8) 
881 (13.2) 
P=0.60  
26 (86.7) 
4 (13.3) 
 
678 (86.1) 
109 (13.9) 
P=0.94 
 
No of chemotherapy separations, 
Median (IQR) 
5 (2-11) 7 (3-14) 
P <0.001 
16 (4-35) 19 (8-36) 
P=0.36 
No of chemotherapy separations, 
Quintiles 
  
P<0.001 
  
P=0.08 
       1–3  357 (41.9) 1,941 (29.1)  7 (23.3) 80 (10.2)  
       4–6 165 (19.4) 1,309 (19.6)  4 (13.3) 71 (9.0)  
       7–9 97 (11.4) 901 (13.5)  - 76 (9.6)  
     10–16 132 (15.5) 1,351 (20.3)  5 (16.7) 154 (19.6)  
      ≥ 17 101 (11.9) 1,168 (17.5)  14 (46.7) 406 (51.6)  
 
IQR = interquartile range (25th–75th percentile)  
Significant ≤ 0.05
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Table 2 Adjusted time-varying Cox Proportional Hazard Models for all-cause mortality between HF and non-HF groups for adults and children.  
Adjusted for age, sex, marital status, country of birth and number of chemotherapy admissions 
 
 
 Adults  N=7,522 (90.2%) Children  N=817 (9.8%)a 
Parameter 
Heart Failure 
HR (95% CI) 
P-value 
Non-HF 
HR (95% CI) 
P-value 
Heart Failure 
HR (95% CI) 
P-value 
Non-HF 
HR (95% CI) 
P-value 
Age (at cancer diagnosis),  
Years  
1.01 (1.01-1.02) P<0.01 1.03 (1.03-1.04) P<0.001 1.02 (0.91-1.15) P=0.73 1.04 (1.01-1.08) P=0.01 
Sex   
Female vs Male 
1.30 (1.10-1.54) P <0.01 1.28 (1.17-1.39) P<0.001 1.09 (0.39-3.09) 
 
P=0.87 
 
0.88 (0.61–1.27) 
 
P=0.50 
Marital Status 
Married/De Facto vs All other 
 
1.16 (0.97-1.38) 
 
P=0.10 
 
1.22 (1.12-1.32) 
 
P<0.001 
 
- 
 
 
- 
 
- 
 
- 
 
Country of Birth 
All Other vs Australia 
 
0.77 (0.64-0.92) 
 
P<0.01 
 
1.06 (0.97-1.16) 
 
P=0.23 
 
- 
 
- 
 
- 
 
- 
 
No of chemotherapy admission         
       1–3  Referent - Referent - Referent  Referent  
       4–6 1.00 (0.95-1.07) P=0.89 0.91 (0.88-0.04) P<0.001 0.83 (0.25-2.81) P=0.77 0.66 (0.39-1.11) P=0.11 
       7–9 0.99 (0.92-1.06) P=0.70 0.93 (0.89-0.96) P<0.001 - - 0.86 (0.63-1.17) P=0.33 
     10–16 0.96 (0.90-1.02) P=0.21 0.94 (0.91-0.97) P<0.001 1.72 (0.50-5.85) P=0.39 0.87 (0.66-1.13) P=0.29 
      ≥ 17 0.98 (0.92-1.05) P=0.54 0.99 (0.96-1.02) P=0.37 1.05 (0.38-2.95) P=0.92 0.91 (0.72-1.15) P=0.45 
HR = hazard ratio 
CI = confidence interval 
 
23 
 
 
Figure legends 
 
Figure 1 Time from cancer diagnosis to the index heart failure admission in N=30 children 
and N=852 adults who underwent chemotherapy treatment for blood cancer and were later 
admitted for heart failure 
 
Figure 2 Survival curves for all-cause mortality of HF and non-HF chemotherapy-receiving 
childhood cancer patients, adjusted by age, sex and number of chemotherapy separations 
 
Figure 3 Survival curves for all-cause mortality of HF and non-HF chemotherapy-receiving 
adult cancer patients, adjusted by age, sex, marital status, country of birth and number of 
chemotherapy separations 
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Figure 1 Time from cancer diagnosis to the index heart failure admission in N=30 children and N=852 adults who underwent chemotherapy 
treatment for blood cancer and were later admitted for heart failure 
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Figure 2 Survival curves for all-cause mortality of HF and non-HF chemotherapy-receiving childhood cancer patients, adjusted by age, sex and 
number of chemotherapy separations 
 
 
 
 
 
  
 Year 
Numbers at 
risk 0 1 2 3 4 5 6 7 8 9 10 11 12 13 
               
Non-HF 787 693 591 530 472 424 371 317 262 214 163 122 75 38 
HF 30 22 17 13 10 9 8 6 5 3 3 3 2 1 
26 
 
Figure 3 Survival curves for all-cause mortality of HF and non-HF chemotherapy-receiving adult cancer patients, adjusted by age, sex, marital 
status, country of birth and number of chemotherapy separations 
 
 
 
  
 Year 
Numbers at 
risk 0 1 2 3 4 5 6 7 8 9 10 11 12 13 
               
Non-HF 6,670 5,169 4,050 3,265 2,469 2,255 1,853 1,487 1,211 949 716 533 318 153 
HF 852 624 468 366 297 242 189 143 112 83 64 45 23 10 
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Diagnosed heart failure  
(N=30) 
All blood cancer records  
(N=30,612) 
Non heart failure  
(N=787) 
Single blood cancer patients 
(N=29,987) 
 
Excl. for multiple cancer 
entries (N=625) 
Chemotherapy-receiving blood 
cancer patients 
(N=8,339) 
Selected blood cancer patients 
(N=23,434) 
Excl. for uniform time period (1996-2009) for 
hospital and death records (N=6,553) 
Excl. non-chemotherapy receiving patients  
(N=15,095) 
Patients aged ≤ 18 
years (N=817) 
Patients aged >18 
years (N=7,522) 
Death 
(N=16) 
Death 
(N=114) 
 
 
Diagnosed heart failure  
(N=852) 
Non heart failure  
(N=6,670) 
Death 
(N=601) 
Death 
(N=2,414 
Figure S1 Population selection flow diagram 
 
 
